{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-061771","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2026-05-15T11:05:36+00:00","discovered_at":"2026-05-15T11:10:00.311202+00:00","generated_at":"2026-05-15T11:10:21.653423+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Traws Pharma Q1 net loss $7.1M; secures up to $60M PIPE financing","bullets":["Net loss of $7.1M ($0.53/share) vs net income of $21.5M in Q1 2025; revenue $0.","R&D expense $4.9M (up 96% YoY) on antiviral trial milestones; cash $3.1M at March 31.","Up to $60M private placement closed April 15 with $10M upfront, expected to fund ops into Q1 2027.","TXM influenza prophylaxis advancing to human challenge trial in Q2 2026; FDA clinical hold unresolved.","New hantavirus program initiated; no approved treatments exist for this disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-061771","json":"https://secwatch.observer/filing/0001104659-26-061771.json","markdown":"https://secwatch.observer/filing/0001104659-26-061771.md","text":"https://secwatch.observer/filing/0001104659-26-061771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926061771/0001104659-26-061771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926061771/tm2614707d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:10:21.653423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dfb4948a2611f33b9df4561bd6e7183ec754cd30","claim":"Traws Pharma, Inc. reported for the quarter ended March 31, 2026 results: revenue $0.0 million, net income $7.1 million, EPS $0.53.","evidence_excerpt":"milestone-based warrants, is sufficient to support planned expenses, including completion of the Challenge Study, into Q1 2027. Revenue for the quarter ended March 31, 2026, was $0.0 million, compared to $0.06 million for the comparable period in 2025. Research and development (R&D) expense for the quarter ended March 31, 2026, totaled $4.9 million, compared to $2.5","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926061771/0001104659-26-061771-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended March 31, 2026"},{"label":"Revenue","value":"$0.0 million"},{"label":"Net income","value":"$7.1 million"},{"label":"EPS","value":"$0.53"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}